Dabrafenib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

**Synonyms:** - BRAF Inhibitor GSK2118436 - Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro- - DABRAFENIB - GSK 2118436 - GSK 2118436A - GSK-2118436 - GSK-2118436A - GSK2118436 - GSK2118436A